DekaBank Deutsche Girozentrale’s Sarepta Therapeutics SRPT Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-30,945	Closed	-$4.35M	–	1332
2025 Q4	$4.35M	Hold	30,945	–	–	0.01%	609
2025 Q3	$573K	Hold	30,945	–	–	﹤0.01%	962
2025 Q2	$526K	Hold	30,945	–	–	﹤0.01%	975
2025 Q1	$2.16M	Hold	30,945	–	–	﹤0.01%	714
2024 Q4	$3.73M	Hold	30,945	–	–	0.01%	632
2024 Q3	$3.83M	Hold	30,945	–	–	0.01%	637
2024 Q2	$4.88M	Hold	30,945	–	–	0.01%	594
2024 Q1	$4M	Hold	30,945	–	–	0.01%	622
2023 Q4	$3.01M	Hold	30,945	–	–	0.01%	690
2023 Q3	$3.82M	Buy	30,945 +945	+3%	+$107K	0.01%	592
2023 Q2	$3.37M	Sell	30,000 -9,310	-24%	-$1.2M	0.01%	643
2023 Q1	$5.31M	Buy	39,310 +1,350	+4%	+$175K	0.01%	534
2022 Q4	$4.8M	Hold	37,960	–	–	0.01%	544
2022 Q3	$4.13M	Hold	37,960	–	–	0.01%	558
2022 Q2	$2.89M	Hold	37,960	–	–	0.01%	645
2022 Q1	$2.98M	Sell	37,960 -700	-2%	-$53.6K	0.01%	670
2021 Q4	$3.51M	Buy	38,660 +1,000	+3%	+$85.5K	0.01%	649
2021 Q3	$3.33M	Sell	37,660 -20,500	-35%	-$1.58M	0.01%	626
2021 Q2	$4.55M	Buy	58,160 +18,170	+45%	+$1.38M	0.01%	544
2021 Q1	$2.91M	Buy	39,990 +2,528	+7%	+$233K	0.01%	607
2020 Q4	$6.42M	Sell	37,462 -1,349	-3%	-$200K	0.02%	399
2020 Q3	$5.5M	Buy	38,811 +34,381	+776%	+$5.22M	0.02%	387
2020 Q2	$717K	Sell	4,430 -124	-3%	-$16.9K	﹤0.01%	728
2020 Q1	$441K	Sell	4,554 -1,599	-26%	-$183K	﹤0.01%	783
2019 Q4	$795K	Sell	6,153 -37,089	-86%	-$3.74M	﹤0.01%	734
2019 Q3	$3.26M	Sell	43,242 -31,938	-42%	-$3.77M	0.02%	426
2019 Q2	$9.76M	Buy	75,180 +45,149	+150%	+$5.49M	0.05%	323
2019 Q1	$4.2M	Buy	30,031 +3,826	+15%	+$492K	0.03%	459
2018 Q4	$2.82M	Sell	26,205 -3,826	-13%	-$478K	0.02%	475
2018 Q3	$4.2M	Buy	30,031 +3,231	+12%	+$442K	0.02%	466
2018 Q2	$3.58M	Sell	26,800 -2,600	-9%	-$245K	0.02%	478
2018 Q1	$2.11M	Buy	29,400 +4,667	+19%	+$311K	0.01%	559
2017 Q4	$926K	Hold	24,733	–	–	0.01%	704
2017 Q3	$926K	Hold	24,733	–	–	0.01%	713
2017 Q2	$825K	Hold	24,733	–	–	0.01%	738
2017 Q1	$718K	Sell	24,733 -2,000	-7%	-$61.9K	0.01%	670
2016 Q4	$758K	Buy	26,733 +2,000	+8%	+$80.3K	0.01%	589
2016 Q3	$1.51M	Hold	24,733	–	–	0.02%	485
2016 Q2	$462K	Buy	24,733 +5,250	+27%	+$97.2K	0.01%	690
2016 Q1	$375K	Sell	19,483 -1,600	-8%	-$28K	﹤0.01%	715
2015 Q4	$815K	Buy	21,083 +200	+1%	+$6.49K	0.01%	594
2015 Q3	$671K	Buy	20,883 +800	+4%	+$27.1K	0.01%	619
2015 Q2	$611K	Buy	20,083 +700	+4%	+$14.3K	0.01%	662
2015 Q1	$257K	Sell	19,383 -2,600	-12%	-$34.7K	﹤0.01%	850
2014 Q4	$319K	Sell	21,983 -2,000	-8%	-$33.9K	﹤0.01%	785
2014 Q3	$506K	Buy	23,983 +600	+3%	+$13.5K	0.01%	651
2014 Q2	$697K	Buy	23,383 +900	+4%	+$28.4K	0.01%	556
2014 Q1	$540K	Buy	22,483 +1,100	+5%	+$28K	0.01%	565
2013 Q4	$444K	Buy	21,383 +3,600	+20%	+$107K	0.01%	562
2013 Q3	$840K	Buy	17,783 +500	+3%	+$19.3K	0.01%	462
2013 Q2	$659K	Buy	+17,283	New	+$618K	0.01%	427

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DekaBank Deutsche Girozentrale's SRPT Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 30,945 shares — an estimated $4.35M sold.

DekaBank Deutsche Girozentrale first reported a position in SRPT in Q2 2013 and held it in 51 quarters. The position peaked at $9.76M in Q2 2019. 344 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 30,945 Sarepta Therapeutics shares in Q1 2026, an estimated $4.35M.
DekaBank Deutsche Girozentrale first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 51 quarters.
DekaBank Deutsche Girozentrale's Sarepta Therapeutics position peaked at $9.76M in Q2 2019.
344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.